Banque Transatlantique SA Sells 6,133 Shares of Edwards Lifesciences Corporation $EW

Banque Transatlantique SA decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 16.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 31,301 shares of the medical research company’s stock after selling 6,133 shares during the period. Banque Transatlantique SA’s holdings in Edwards Lifesciences were worth $2,668,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. MidFirst Bank bought a new stake in Edwards Lifesciences in the 4th quarter valued at $298,000. Kera Capital Partners Inc. grew its holdings in Edwards Lifesciences by 8.8% in the 4th quarter. Kera Capital Partners Inc. now owns 6,006 shares of the medical research company’s stock valued at $489,000 after buying an additional 488 shares in the last quarter. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth $26,000. Compound Planning Inc. lifted its holdings in shares of Edwards Lifesciences by 20.9% during the fourth quarter. Compound Planning Inc. now owns 3,921 shares of the medical research company’s stock worth $334,000 after buying an additional 678 shares in the last quarter. Finally, Harbour Wealth Management Group Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $237,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $87.51 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.60. The firm has a market cap of $50.39 billion, a P/E ratio of 46.55, a P/E/G ratio of 2.17 and a beta of 0.87. The company’s 50-day moving average price is $83.27 and its two-hundred day moving average price is $83.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EW. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Finally, Evercore reissued an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.96.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 81,038 shares of company stock valued at $6,683,255 over the last ninety days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.